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ABSTRACT 
The basic aim of the present investigation is to formulate and evaluate colon specific press coated tablets of Esomeprazole. Esomeprazole tablets 
were successfully prepared using enteric coated polymers ethyl cellulose and HPMC pthallate by first preparing the core tablets and then press 
coated with polymers. study of the preformulation characteristics and FTIR studies indicates that there was no interaction between 
Esomeprazole and excipients used  in the formulation .Invitro release profiles of optimized form of F6 were found to showed delayed release 
pattern in a very customized manner which was very much required for the colon specific drug delivery. . In vitro release profiles of optimized 
formulation of Esomeprazole controlled release tablets (F-6) were found to be improvised and followed zero - order kinetics, hence the release 
of the drug from the dosage form was independent of concentration and followed Higuchi model, and hence release of drug from press coated 
tablet was by diffusion mechanism. The drug delivery system was designed to deliver the drug at such a time when it was needed nocturnal time. 
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INTRODUCTION 
Colon is being extensively investigated as a drug 
delivery site. Oral colon-specific drug delivery system 
(CDDS) has been developed by means of combination of 
one or more controlled release mechanisms, hardly 
releases drug in the upper part of the gastrointestinal 
(GI) tract, but rapidly releases drug in the colon 
following oral administration CDDS is  convenient for 
treating localized colonic diseases, i.e. ulcerative colitis, 
Crohn’s disease and constipation etc., CDDS, also 
selectively deliver drug to the colon, but not to the upper 
GI tract. Colon is referred to as the optimal absorption 
site for protein and polypeptide after oral 
administration, because of the existence of relatively low 
proteolytic enzyme activities and quite long transit 
time in the colon [1.2].  CDDS would be advantageous 
when a delay in absorption is desirable from 
a therapeutically point of view, as for the treatment of 
diseases that have peak symptoms in the early 
morning and that exhibit circadian rhythms, such as 
nocturnal asthma, angina and rheumatoid 
arthritis. A large number of polysaccharides such as 
pectin, amylose, guar gum, chitosan, inulin, 
cyclodextrins, chondroitin sulphate, dextrans, dextrin and 
locust bean gum have been investigated for their use 
in colon targeted drug delivery systems.3 Esomeprazole 
belongs to a group of drugs called proton pump inhibitors. It 
decreases the amount of acid produced in the stomach. 
Esomeprazole is used to treat and prevent stomach and 
intestinal ulcers, erosive esophagitis (damage to the 
esophagus from stomach acid), and other conditions 
involving excessive stomach acid such as Zollinger-Ellison 
syndrome 4. In Peptic ulcer patients, gastric distress occurs is 
most likely in the late night and early morning hours. 
Ulcerative pain frequently occurs after stomach emptying, 
following daytime meals and in the very early morning, 
disrupting sleep. This is attributed to high gastric secretion 
and slows gastric motility and emptying at night. 
Suppression of nocturnal gastric acid secretion is an 
important factor in duodenal ulcer healing. Once daily 
nocturnal administration of proton pumps inhibitor 
medications not only reduce acid secretion more effectively 
but also promote ulcer healing and reduce ulcer occurrence. 
The rational of this study is to design and evaluate an oral 
site-specific colon drug delivery system containing 
Esomeprazole, which can be targeted to colon in a pH and 
time dependent manner. 
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MATERIALS  
Esomeprazole was obtained as a gift sample from hetero labs 
and ethylcellulose, microcrystallinecellulose, crosspovidone, 
crosscaramellose sodium, sodium starch 
glycollate,magnesium sterate,hydroxy propyl methyl 
cellulose were obtained from merck specialities pvt ltd, 
Mumbai, India used in the formulation of tablets. 
METHODOLOGY 
 Formulation of core tablets by direct compression: 
The inner core tablets were prepared by using direct 
compression method. As  shown  in  Table  1 powder 
mixtures  of  Esomeprazole,  microcrystalline cellulose  (MCC, 
Avicel  PH-102), cross-carmellose sodium (Ac-Di-Sol), SSG, 
crospovidone,  ingredients were dry blended for  20  min.  
Followed by addition of Magnesium Stearate. The mixtures 
were then further blended for 10 min., 150mg of resultant 
powder blend was manually compressed using KBr hydraulic 
press at a pressure of 1 ton, with a 8mm round punch and die 
to obtain the core tablet. 
Formulation of mixed blend for barrier layer: 
The various formulations containing Ethylcellulose and 
HPMC in different compositions were weighed dry blended at 
about 10 min and used as press-coating material to prepare 
press-coated tablets respectively by direct compression 
method. 
Preparation of press-coated tablets: 
The core tablets were press-coated with 400mg of mixed 
blend/granules as given in Table 3. 200mg of barrier layer 
material was weighed and transferred into a 12mm die then 
the core tablet was placed manually at the center. The 
remaining 200mg of the barrier layer materiel was added 
into the die and compressed at a pressure of 5 tons for 3min 
using KBr hydraulic press. 
Preparation of enteric coating solution: 
 Polymer solution was prepared with HPMC phthalate, myvacet 
and colour in ethanol as solvent. 
Formulation of esomeprazole tablets (colon targeting 
drug delivery) 
 
Table 1: Formulation for core tablet: 
S.No. Ingredients F 1 F 2 F 3 F 4 F 5 F 6 F7 F8 F9 
 1. Esomeprazole 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 
2. 
Micro crystalline 
cellulose 
q.s 
q.s q.s q.s q.s q.s q.s q.s q.s 
3. Cross povidone 3.6 mg 5.4 mg 9.0 mg       
4. 
Cross caramellose 
sodium 
   3.6 mg 5.4 mg 9.0 mg    
5. Sodium starch glycolate       3.6 mg 5.4 mg 9.0 mg 
6. Magnesium stearate 2mg 2 mg 2 mg 2 mg 2 mg 2 mg 2 mg 2 mg 2 mg 
 Total wt 150mg 150mg 150mg 150mg 150mg 150mg 150mg 150mg 150mg 
   
Table 2: Formulation for press coat 
Press coat  P1F6 P2F6 P3F6 P4F6 P5F6 
HPMC 400 100 300 200 0 
E.C 0 300 100 200 400 
Total wt 400mg 400mg 400mg 400mg 400mg 
Eneteric coated formula 
HPMC phthalate 55 17.17mg 
Myvacet 1.72mg 
Ferric oxide (red) 2.58mg 
Ethanol q.s 
 
Preformulation Studies 
Preformulation studies are performed to investigate the 
physical and chemical properties of a drug substance alone 
and also when combined with other substances such as 
excipients. It is the first step in the rational development of 
dosage forms.The use of preformulation parameters 
maximizes the chances in formulating an acceptable, safe, 
efficacious and stable product and at same time provides the 
basis for optimization of the drug product quality. 
Preparation of standard calibration curve of 
esomeprazole in 0.1N HCl 
Preparation of standard solution:  
Standard stock solution of Esomeprazole was prepared in 
0.1N HCL. 100 mg of Esomeprazole was accurately weighed 
into 100ml volumetric flask and dissolved in small quantity 
of buffer. The volume was made up with water to get a 
concentration of 1000µg/ml (SS-I). 
From this 10 ml solution was withdrawn and diluted to 
100ml of 0.1N HCL to get a concentration of 100µg/ml (SS-
II). 
Preparation of working standard solutions:  
Further, from (SS-II) aliquots of 0.3ml, 0.6ml, 0.9ml, 1.2ml, 
1.5ml and 1.8ml were pipetted into 10ml volumetric flasks. 
The volume was made up with 0.1N HCL to get the final 
concentrations of 3,6,9,12,15 and 18µg/ml respectively. The 
absorbance of each concentration was measured at 
285nm.The data are compiled in Table and plotted a graph.  
λ Max :285nm.  
Beer’s range: 3-18 µg /ml. 
Preparation of standard calibration curve of 
esomeprazole in pH 6.8 Phosphate Buffer 
Preparation of standard solution:  
Standard stock solution of Esomeprazole was prepared in 
Phosphate buffer pH6.8. 100 mg of Esomeprazole was 
accurately weighed into 100ml volumetric flask and 
dissolved in small quantity of buffer. The volume was made 
up with water to get a concentration of 1000µg/ml (SS-I). 
From this 10 ml solution was withdrawn and diluted to 
100ml of phosphate buffer pH6.8 to get a concentration of 
100µg/ml (SS-II). 
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Preparation of working standard solutions:  
Further, from (SS-II) aliquots of 0.3ml, 0.6ml, 0.9ml, 1.2ml, 
1.5ml and 1.8ml were pipetted into 10ml volumetric flasks. 
The volume was made up with phosphate buffer pH6.8 to get 
the final concentrations of 3,6,9,12,15 and 18µg/ml 
respectively. The absorbance of each concentration was 
measured at 285nm.The data are compiled in Table and 
plotted a graph.  
λ Max :285nm.  
Beer’s range: 3-18 µg /ml. 
Flow Properties: 
Angle of Repose: 
The flow property was determined by measuring the Angle 
of Repose. In order to determine the flow property, the Angle 
of Repose was determined. It is the maximum angle that can 
be obtained between the free standing surface of a powder 
heap and the horizontal. 
Angle of repose= tan-¹ (h/r) 
Where,  
h = height of a pile (2 cm)     r = radius of pile base. 
Bulk density: 
Bulk density is ratio of given mass of powder and its bulk 
volume. Bulk density was determined by measuring the 
volume of known mass of powder sample that has been 
passed through the screen in to graduated cylinder or 
through volume measuring apparatus in to cup. 
Bulk density = M / V0 
Where M= mass of the powder; 
            V0=bulk volume of the powder. 
Limits: 
It has been stated that the bulk density values having less 
than 1.2 g/cm3 indicates good packing and values greater 
than 1.5 g/cm3 indicates poor packing. 
Tapped density: 
A known quantity of powder was transferred to a graduated 
cylinder and volume V0 was noted.The cylinder fixed to a 
density determination apparatus, tapped for 500 times then 
reading was 
Observed. The density is achieved by mechanically tapped by 
a measuring cylinder containing the powder sample. After 
observing the initial volume the cylinder is mechanically 
tapped and volume reading were taken until little further 
volume changes is observed. 
Tap density = M / Vr 
Where M = mass of the powder,  
            Vr = final tapping volume of the powder. 
Compressibility index and Hausner’s ratio: 
The compressibility index and Hausner’s ratio may be 
calculated using measured values of bulk density and tapped 
density as follows: 
Compressibility index = 100 × tapped density / bulk density 
Hausner’s ratio = tapped density / bulk density 
Flow properties and corresponding Angle of repose, 
Compressibility index and Hausner’s ratio: 
 
Table 3: acceptance criteria of flow properties 
S. No Flow properties Angle of repose(θ)      Compressibility Index (%)       Hausner ratio 
1. Excellent 25-30 <10 1.00-1.11 
2. Good 31-35 11-15 1.12-1.18 
3. Fair 36-40 16-20 1.19-1.25 
4. Passable 41-45 21-25 1.26-1.34 
5. Poor 46-55 26-31 1.35-1.45 
6. Very poor 56-65 32-37 1.46-1.59 
7. Very very poor > 66 >38 >1.6 
 
Angle of repose: 
The friction forces in a loose powder can be measured by the 
angle of repose (q). It is an indicative of the flow properties 
of the powder. It is defined as maximum angle possible 
between the surface of the pile of powder and the horizontal 
plane 
Tan θ=h/r 
Where h and r are the height of pile and radius of the base of 
pile. 
Table 4: Relationship between Angle of Repose (θ) and 
flow properties 
Angle of Repose (θ) (degrees) Flow 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
 
Different ranges of flowability in terms of angle of repose are 
given below in the table no.4 
Drug – Excipient Compatibility Study 6: 
Drug is in intimate contact with one or more excipient in all 
the dosage forms. Later it could affect the stability of drug. 
Knowledge of drug excipient interaction is useful in selecting 
an appropriate excipient. 
Procedure: 
API and excipient are taken in the ratios above mentioned 
and mixed together in a polybag for 5 min. Each mixture is 
allotted sample code for identification. 4 sets of sample were 
allocated where each sample mixture is divided in to 1g in to 
its corresponding glass vial (USP Type I) at different 
conditions. 
.All vials are properly sealed and loaded at respective 
conditions. The samples are to be checked for its Description, 
Related substance and water content by KF. 
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Release kinetics 11: 
Mathematical models are used to evaluate the kinetics and 
mechanism of drug release from the tablets. The model that 
best fits the release data is selected based on the correlation 
coefficient (R) value in various models. The model with high 
‘R’ value is considered as the best fit on the release data. 
 Zero order release: 
The equation for zero order release is represented as 
Qt = Qo + Kot 
Where, Qt = amount of drug released in time (t)  
QO = initial amount of drug in solution  
KO = zero order release constant  
First order release: 
The equation for the first order release is represented as 
Log C = Log C0 – Kt / 2.303 
 where, C = amount of drug remaining unreleased at time (t)  
 CO = initial amount of drug in solution 
 K = first order rate constant  
Higuchi’s model: 
The simplified Higuchi equation is represented as  
Qt = Kt
 ½ 
where, Qt = amount of drug released in time (t)  
 K = Higuchi’ constant 
A linear relationship between amount of drug released (Q) 
versus square root of time (t1/2) is observed if the drug release 
from the matrix is diffusion controlled. 
Hixson-Crowell model:  
The simplified Hixson-Crowell equation is represented as  
Qo1/3
 
– Qt1/3 = Kt 
where, Qt = amount of drug released in time (t)  
 QO = initial amount of drug in solution 
 K = cube root constant  
A graphic representation of cubic root of unreleased fraction 
of drug versus time will be   linear if geometric shape of the 
formulation diminishes proportionally over time.  
Korsmeyer- Peppas model:  
The Korsmeyer-Peppas model relates drug release 
exponentially to time. It is represented as 
Mt / Minf = Kt
n 
where, Mt / Minf = fractional release of drug  
K = constant depending on structural and geometric 
characteristics of the drug       dosage form  
n = release exponent  
The value of n indicates the drug release mechanism. For a 
slab the value n = 0.5 indicates Fickian diffusion and values 
of n between 0.5 and 1.0 indicate non-Fickian mechanism. In 
case of a cylinder n = 0.45 instead of 0.5, and 0.89 instead of 
1.0. This model is used to analyze the release of drug from 
polymeric dosage forms, when the release mechanism is not 
understood or when there is a possibility of more than one 
type of release mechanisms are involved. 
RESULTS AND DISCUSSION 
The quantitative evaluation and assessment of a tablets 
chemical, physical and bioavailability properties are 
important in the design of tablets and to monitor product 
quality. There are various standards that have been set in the 
various pharmacopoeias regarding the quality of 
pharmaceutical tablets. These include the diameter, size, 
shape, thickness, weight, hardness, disintegration and 
dissolution characters 
1. Weight variation: 
20 tablets were selected randomly from the batch and 
weighted individually to check for weight variation. Weight 
variation specification as per I.P. is shown in table No. 4 
Table 5: Weight Variation Specification as per IP 
 Average Weight of Tablets %Deviation 
80 mg or less ±10 
More than 80 mg but less than 250 mg ±7.5 
250 mg or more ±5 
 
 Hardness: 
Hardness is the force required to break a tablet in a 
diametric compression was measured using Monsanto tablet 
hardness tester and also Pfizer, strong cobb and erwika 
testers. It is expressed in kg/cm2. 
 Thickness: 
Three tablets were selected randomly from each batch and 
thickness was measured by using Vernier Caliper. 
 Friability (F): 
Friability of the tablet determined using Roche friabilator. 
This device subjects the tablet to the combined effect of 
abrasion and shock in a plastic chamber revolving at 25 rpm 
and dropping a tablet at the height of 6 inches in each 
revolution. Pre weighed sample of tablets was placed in the 
friabilator and were subjected to the 100 revolutions. 
Tablets were dusted using a soft muslin cloth and reweighed. 
The friability (F) is given by the formula. 
 
Disintegration test: 
First step in the approach of drug absorption process 
disintegration is the important step where the drug  
Disintegration time: Uncoated tablet: 5-30 minutes. 
Coated tablet: 1-2 hours 
In-vitro release studies 7,8   
Tablet was introduced into the basket of the LABINDIA TS 
8000 USP dissolution test apparatus and the apparatus was 
set in motion at 50 rpm for time period of 1 hr, 5 ml of 
sample was withdrawn for every 5min intervals and 
replaced by pH6.8 phosphate buffer solutions. Samples 
withdrawn were analyzed by UV spectrophotometer for 
presence of drug using buffer solution as blank.  
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In-vitro Dissolution methods for Enteric press-coated 
tablets8,9,11 :  
In –vitro Dissolution  studies  of  colon targeted drug  
delivery  systems  was done with  the conventional paddle 
method of press coated tablets were performed at 37  ± 0.5 °C 
using 0.1N HCL in USP II paddle method at 50 rpm for first two 
hours and replaced with pH6.8  phosphate buffer. 5 ml of 
filtered aliquot was manually withdrawn at pre-determined 
time intervals and replaced with 5 ml of fresh buffer solution 
maintained at the same temperature. The samples were 
analyzed at 285nm using a UV spectrophotometer. The lag 
time and percentage release was   determined of the each 
formulation. 
Table 6: concentration and absorbance of Esomeprazole 
in 0.1N HCL 
S.No Concentration Absorbance 
1 0 0 
2 3 0.0729 
3 6 0.1559 
4 9 0.2339 
5 12 0.3118 
6 15 0.3798 
7 18 0.4682 
 
 
Figure 1: calibration curve of Esomeprazole 
Table 7: concentration and absorbances of 
Esomeprazole in 6.8 pH Phosphate buffer 
S.No Concentration Absorbance 
1 0 0 
2 3 0.121 
3 6 0.238 
4 9 0.354 
5 12 0.475 
6 15 0.586 
7 18 0.702 
 
Drug Excipient Compatibility Studies 
 
Figure 2: FTIR Spectra of Esomeprazole 
 
Figure 3: FTIR Spectra of Esomeprazole optimized formulation 
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 Pre-compression Parameters 
Table 8: Pre-compression parameters 
Formulations 
 
Angle of 
Repose (θ) 
Loose Bulk 
Density (g/ml) 
Tapped Bulk 
Density (g/ml) 
%Compressibility Hausner’s 
ratio 
F1 210 55’ 0.510 0.583 12.52 1.14 
F2 220 43’ 0.416 0.482 13.69 1.15 
F3 250 02’ 0.423 0.495 14.54 1.17 
F4 240 18’ 0.309 0.353 12.46 1.14 
F5 260 89’ 0.306 0.355 13.80 1.16 
F6 220 57’ 0.322 0.376 14.36 1.16 
F7 250 98’ 0.404 0.472 14.40 1.16 
F8 260 42’ 0.511 0.576 11.28 1.12 
F9 240 62’ 0.506 0.577 12.30 1.14 
F10 270 08’ 0.422 0.493 14.37 1.16 
 
From the above pre-compression parameters it was clear evidence that drug and excipients has good flow properties and 
suitable for direct compression. 
Table 9: Evaluation for rapid release core 
S.  
No 
Physical  parameter F 1 F 2 F 3 F  4 F 5 F 6 F 7 F 8 F 9 
 
F10 
 
1 Avg Weight (mg) 151 150 148 149 152 150 150 149 148 149 
2 Hardness (Kg/cm2) 5.1 5.3 5.6 5.1 5.2 5.3 5.4 5.7 5.8 5.4 
3 Thickness (mm) 3.51 3.48 3.51 3.5 3.5 3.47 3.49 3.52 3.61 3.55 
4 Friability % 0.33 0.46 0.41 0.50 0.54 0.45 0.35 0.39 0.37 0.45 
5 Disintegration time 
3min 
42sec 
3min 
52sec 
3min 
4sec 
3min 
21sec 
2min 
16sec 
2min 
08sec 
4min 
34sec 
3min 
48sec 
3min 
26sec 
3min 
25sec 
 
In vitro dissolution for core tablets were done in 6.8 phosphate buffer and enteric press coated tablets were initially placed in 
acidic stage and next was changed with phosphate buffer. 
Core tablets:- 
Table 10: Dissolution for core tablet 
Dissolution time(Min) F1 F2 F3 F4 F5 F6 F7 F8 F9 
5 14.4 16.2 16.1 10.4 12.1 19.1 15.0 16.4 20.4 
10 22.4 30.5 10.8 18.4 22.1 35.4 24.1 28.9 27.8 
20 37.3 40.1 46.8 35.4 51.7 65.4 45.6 48.6 33.5 
30 52.4 73.9 73.4 60.4 66.3 76.1 66.6 61.4 41.6 
45 76.0 79.4 80.3 72.6 75.4 82.0 75.4 72.4 60.4 
60 80.1 82.2 85.4 81.5 88.7 97.6 80.4 79.6 77.6 
 
 
Figure 4: Dissolution graph for formulations F1-F9 
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Evaluation for Press coated tablets 
                                                           Table 11: Evaluation data for Press coated tablets 
S.  No Physical  parameter P1F6 P2F6 P3F6 P4F6 P5F6 
1 Avg Weight (mg) 551 550 549 549 550 
2 Hardness (Kg/cm2) 7.4 7.0 7.7 7.4 7.5 
3 Thickness (mm) 2.45 2.49 2.5 2.51 2.5 
4 Friability % 0.5 0.45 0.46 0.36 0.24 
 
Table 12: Dissolution for Enteric press coat 
Time in hrs P1F6 P2F6 P3 F6 P4 F6 P5 F6 
                                              0.1N HCL 
1 0 0 0 0 0 
2 0 0 0 0 0 
 6.8 pH Phosphate buffer  
3 8 19 6 4 7 
4 15 30 8.9 16 18 
5 19 54 15.3 29 25 
6 22 79 20.5 42 33 
7 39 81 48.9 72 40 
8 79 94 98.4 92 75 
 
Graph for enteric press coat formulation 
 
Figure 5: Graph showing % CDR verses time in hrs for formulations P1F6 to P5F6 
 
Kinetics of In Vitro Drug Release: 
The dosage forms most commonly release the drug either in 
the zero order or in the first order pattern.  Controlled 
release dosage forms of Esomeprazole were prepared and 
studied for their dissolution behavior.  In vitro release data of 
time points between 1 to 24 hours were considered and 
treated for kinetic principles. The regression values of 
release kinetics of optimized formulation were shown in the 
table 13. 
 
Table 13: Regression values of release kinetics 
                                           0.1 N HCl 4.5 Acetate buffer 6.8 phosphate buffer 
Zero order 0.9263 0.921 0.8475 
First order 0.8792 0.8957 0.7986 
Higuchi 0.9922 0.9928 0.965 
Korsmeyer-Peppas 0.9873 0.9809 0.9588 
Hixson-Crowell 0.9461 0.9814 0.9058 
 
The regression values of zero order are higher than the 
regression values of first order indicating that the release of 
drug is independent of the concentration. When the 
regression values of Higuchi, Korsmeyer-Peppas, and 
Hixson-Crowell were considered, the regression values were 
higher for Higuchi in all three mediums. It indicated that the 
drug was released through diffusion mechanism from the 
dosage form. 
CONCLUSION 
Press coated tablets of Esomeprazole (F-I- F-IX) were 
successfully prepared using enteric coated polymers ethyl 
cellulose and HPMC pthallate by first preparing the core 
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tablets and then press coated with polymers.The tablets 
were evaluated for physical properties and in-vitro 
dissolution studies. Based on the results, F-6 was identified 
as better formulation amongst all formulations. 
In vitro release profiles of optimized formulation of 
Esomeprazole colon specific release tablets (F-6) were found 
to be improvised to that of reference drug release profile i.e., 
100 % drug release was achieved..The manufacturing 
procedure was standardized and found to be reproducible.  
Esomeprazole release from the tablets of F-6 formulation 
followed zero - order kinetics, hence the release of the drug 
from the dosage form was independent of concentration and 
followed Higuchi model, and hence release of drug from 
matrix was by diffusion mechanism. 
By this we can conclude that the colon specific drug release 
formulation of Esomeprazole developed is the promising 
system for the treatment of stomach and intestinal ulcers   
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